Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Other Non Operating Income: 2019-2025

Historic Other Non Operating Income for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to -$253,000.

  • Keros Therapeutics' Other Non Operating Income fell 175.00% to -$253,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 million, marking a year-over-year decrease of 55.61%. This contributed to the annual value of -$954,000 for FY2024, which is 363.11% down from last year.
  • Latest data reveals that Keros Therapeutics reported Other Non Operating Income of -$253,000 as of Q3 2025, which was down 14.48% from -$221,000 recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Other Non Operating Income ranged from a high of $762,000 in Q3 2022 and a low of -$1.4 million during Q4 2022.
  • For the 3-year period, Keros Therapeutics' Other Non Operating Income averaged around -$179,273, with its median value being -$196,000 (2024).
  • Within the past 5 years, the most significant YoY rise in Keros Therapeutics' Other Non Operating Income was 656.20% (2022), while the steepest drop was 1,288.12% (2022).
  • Keros Therapeutics' Other Non Operating Income (Quarterly) stood at -$101,000 in 2021, then crashed by 1,288.12% to -$1.4 million in 2022, then soared by 103.99% to $56,000 in 2023, then slumped by 508.93% to -$229,000 in 2024, then tumbled by 175.00% to -$253,000 in 2025.
  • Its last three reported values are -$253,000 in Q3 2025, -$221,000 for Q2 2025, and -$338,000 during Q1 2025.